Greater Cannabis Company (GCAN) Accounts Payables (2017 - 2026)
Greater Cannabis Company's (GCAN) quarterly Accounts Payables came in at $7514.0 in Q1 2026, down 6.59% year-on-year from $8044.0 in Q1 2025, and down 11.75% quarter-over-quarter from $8514.0 in Q4 2025.
Greater Cannabis Company (GCAN) Accounts Payables (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Accounts Payables history runs 10 years deep, the most recent figure standing at $7514.0 for Q1 2026.
- On a quarterly basis, Accounts Payables fell 6.59% year-over-year to $7514.0 in Q1 2026; TTM through Mar 2026 was $7514.0, a 6.59% decrease from a year earlier, with the FY2025 full-year figure at $8514.0, up 8.06% from the prior year.
- Accounts Payables slipped to $7514.0 in Q1 2026 per GCAN's latest filing, from $8514.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $16251.0 in Q4 2022 and bottomed at $3340.0 in Q3 2023.
- The 5-year median for Accounts Payables is $7514.0 (2026), against an average of $8126.2.
- Across the five-year window, Accounts Payables jumped 333.56% in 2022 and slumped 76.64% in 2023, its largest moves.
- Year by year, Accounts Payables stood at $16251.0 in 2022, then tumbled by 62.5% to $6094.0 in 2023, then increased by 29.29% to $7879.0 in 2024, then increased by 8.06% to $8514.0 in 2025, then slipped by 11.75% to $7514.0 in 2026.
- Per Business Quant, the three latest GCAN Accounts Payables figures stand at $7514.0 (Q1 2026), $8514.0 (Q4 2025), and $8849.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 507.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1.67 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | 7,514.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,514.00 |
| Dec 31, 2025 | 8,514.00 |
| Sep 30, 2025 | 8,849.00 |
| Jun 30, 2025 | 6,793.00 |
| Mar 31, 2025 | 8,044.00 |
| Dec 31, 2024 | 7,879.00 |
| Sep 30, 2024 | 6,418.00 |
| Jun 30, 2024 | 5,259.00 |
| Mar 31, 2024 | 6,259.00 |
| Dec 31, 2023 | 6,094.00 |
| Sep 30, 2023 | 3,340.00 |
| Jun 30, 2023 | 5,340.00 |
| Mar 31, 2023 | 5,993.00 |
| Dec 31, 2022 | 16,251.00 |
| Sep 30, 2022 | 14,297.00 |
| Jun 30, 2022 | 8,346.00 |
| Mar 31, 2022 | 12,955.00 |
| Dec 31, 2021 | 11,705.00 |
| Sep 30, 2021 | 8,442.00 |
| Jun 30, 2021 | 1,925.00 |